A Phase 3 interventional study of Evolocumab and Placebo in Subjects With Hyperlipidemia, Dyslipidemia, sponsored by Amgen. Completed at 15 sites in 3 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-23.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.
Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 13th largest by enrollment, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 15th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →
evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 307 across the 21 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
17 studies in Hyperlipidemias by Amgen: none open now, none under way, none of them phase 3. Of 17 finished, 17 (100%) have results posted.
Among the 17 studies in Hyperlipidemias by Amgen, this one is the 14th largest by enrollment, is one of 2 that started in 2016, is one of 11 in phase 3, and was the 15th registered.
Amgen’s Hyperlipidemias studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing evolocumab in Hyperlipidemias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 17 in Hyperlipidemias:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
This study's enrollment of 129 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Hyperlipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
Drug: Placebo
Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
Drug: Evolocumab
Administered subcutaneously once a month using an autoinjector/pen.
Also known as: Repatha, AMG 145
Administered subcutaneously once a month using an autoinjector/pen.
Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16
Arterial inflammation was assessed using 18F-fluoro-deoxyglucose positron-emission tomography/computed tomography (18F-FDG PET/CT). Arterial 18F-FDG uptake is correlated with arterial macrophage content and predicts cardiovascular events. Images were analyzed by an experienced radiologist blinded to all patient characteristics. The maximum standardized uptake value was calculated as a time- and dose- corrected tissue radioactivity divided by body weight in the index and the target-to-background ratio (TBR) was calculated from the ratio of the standardized uptake value of the artery compared to mean background venous activity. The average maximum TBR for the most diseased segment (MDS) was calculated from a group of 3 contiguous slices (approximately 1.5 cm), centered on the slice with the highest maximum TBR in the index vessel. The index vessel was defined as the vessel (either the right or left carotid or aorta) with the highest mean TBR at baseline.
Time frame: Baseline and week 16
Percent Change From Baseline in Lipoprotein(a) Concentration at Week 16
Time frame: Baseline and week 16
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration at Week 16
Time frame: Baseline and week 16
Percent Change From Baseline in Apolipoprotein B Concentration at Week 16
Time frame: Baseline and week 16
This study was conducted at 14 centers in Canada, the Netherlands, and the United States. Participants were enrolled from 14 April 2016 to 07 December 2017.
| Milestone | Placebo | Evolocumab 420 mg QM |
|---|---|---|
| Started | 64 | 65 |
| Completed | 64 | 64 |
| Not completed | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 1 |
Arterial inflammation was assessed using 18F-fluoro-deoxyglucose positron-emission tomography/computed tomography (18F-FDG PET/CT). Arterial 18F-FDG uptake is correlated with arterial macrophage content and predicts cardiovascular events. Images were analyzed by an experienced radiologist blinded to all patient characteristics. The maximum standardized uptake value was calculated as a time- and dose- corrected tissue radioactivity divided by body weight in the index and the target-to-background ratio (TBR) was calculated from the ratio of the standardized uptake value of the artery compared to mean background venous activity. The average maximum TBR for the most diseased segment (MDS) was calculated from a group of 3 contiguous slices (approximately 1.5 cm), centered on the slice with the highest maximum TBR in the index vessel. The index vessel was defined as the vessel (either the right or left carotid or aorta) with the highest mean TBR at baseline.
| percent change | Placebo | Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline in Maximum Target-to-background Ratio in the Most Diseased Segment of the Index Vessel at Week 16 | -5.31 ± 1.67 | -8.31 ± 1.67 |
| percent change | Placebo | Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline in Lipoprotein(a) Concentration at Week 16 | 1.06 ± 1.94 | -12.83 ± 1.92 |
| percent change | Placebo | Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) Concentration at Week 16 | 1.64 ± 1.86 | -59.02 ± 1.82 |
| percent change | Placebo | Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B Concentration at Week 16 | 3.29 ± 1.53 | -48.30 ± 1.51 |
Collected over From the first dose of study drug up to 30 days after the last dose or until the end of study date, whichever was earlier; the maximum duration of treatment was 3.9 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QM | 0/64 (0%) | 0/64 (0%) | 47/64 (73.4%) |
| Evolocumab 420 mg QM | 0/65 (0%) | 2/65 (3.1%) | 49/65 (75.4%) |
| Event | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/64 | 1/65 |
| NephrolithiasisRenal and urinary disorders | 0/64 | 1/65 |
| Event | Placebo QM | Evolocumab 420 mg QM |
|---|---|---|
| NasopharyngitisInfections and infestations | 13/64 | 6/65 |
| HeadacheNervous system disorders | 7/64 | 4/65 |
| InfluenzaInfections and infestations | 3/64 | 7/65 |
| DiarrhoeaGastrointestinal disorders | 5/64 | 1/65 |
| NauseaGastrointestinal disorders | 5/64 | 1/65 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/64 | 5/65 |
| Influenza like illnessGeneral disorders | 4/64 | 4/65 |
| InsomniaPsychiatric disorders | 0/64 | 4/65 |
| Chest painGeneral disorders | 3/64 | 0/65 |
| Urinary tract infectionInfections and infestations | 3/64 | 1/65 |
| Age, Continuous(years) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| Mean | 60.7 ± 7.6 | 60.0 ± 6.8 | 60.3 ± 7.2 |
| Age, Customized(Participants) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| 18 - 64 years | 41 | 48 | 89 |
| ≥ 65 years | 23 | 17 | 40 |
| Sex: Female, Male(Participants) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| Female | 30 | 39 | 69 |
| Male | 34 | 26 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 64 | 64 | 128 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 2 | 5 |
| Black or African American | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White | 58 | 58 | 116 |
| Other | 0 | 1 | 1 |
| Location of the Index Vessel Used for Calculation of Maximum Target-to-background Ratio(Participants) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| Ascending thoracic aorta | 54 | 49 | 103 |
| Left common carotid | 1 | 3 | 4 |
| Right common carotid | 8 | 11 | 19 |
| Missing | 1 | 2 | 3 |
| Maximum Target-to-background Ratio (TBR) in the Most Diseased Section of the Index Vessel(ratio) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| Mean | 2.28765 ± 0.41284 | 2.29667 ± 0.46063 | 2.29216 ± 0.43566 |
| Stratification Factor: Baseline Statin Therapy(Participants) | Placebo | Evolocumab 420 mg QM | Total |
|---|---|---|---|
| Yes | 33 | 34 | 67 |
| No | 31 | 31 | 62 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Apr 2018, 23 months.
Results were first posted in Apr 2019, 1 year after primary completion.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab